Mike Tyson Unveils New Cannabis Brand in New York

Business by 2FIRSTS.ai
Jan.22.2024
Mike Tyson Unveils New Cannabis Brand in New York
Hundreds of Mike Tyson fans lined up outside a New York pharmacy to support his new marijuana business venture.

According to a recent report by The New York Times, hundreds of followers of Mike Tyson, one of the greatest boxers of all time, lined up at a pharmacy in New York over the weekend in hopes of getting a chance to meet him and show support for his latest business venture: selling marijuana in his home state.

 

According to reports, 57-year-old Tyson has recently launched the Tyson 2.0 brand, emerging as one of the most notable newcomers in the New York cannabis industry. As the legalization of cannabis gradually spreads across the United States, actors, athletes, and musicians have been profiting from the marijuana industry through product lines and sponsorship contracts for over a decade. However, the trend has only recently started to gain momentum in New York. Tyson is seeking to test his fame and become a prominent figure in what is projected to become the world's largest and most competitive market.

 

The evaluations of cannabis brands backed by celebrities are mixed. While their sales often surpass those of traditional brands, they cannot compete with the biggest brand that sells millions of dollars worth of cannabis every month.

 

According to data from Headset, a specialized cannabis data company, out of the top 30 bestselling brands in California, the largest market in the United States, only 9 of them are owned or endorsed by celebrities. These include Tyson 2.0, actor Seth Rogen's Houseplant, and musician Carlos Santana's Mirayo.

 

One of the company analysts, Mitchell Laferla, noted that the ultimate driving factor for consumers in emerging markets like New York is value, and this is precisely where celebrity-endorsed brands face difficulties.

 

Consumers who spend lavishly are now seeking the most powerful features at the lowest prices, while the quality of celebrity brands varies, often commanding higher prices. In California, a bag of 3.5 grams typically sells for around $23.14, whereas Tyson 2.0 is priced at approximately $28.44, representing a 23% difference.

 

Lafra states that the success of Tyson 2.0 can be attributed to the way Tyson interacts with its clients and their companies, its proactive expansion into new markets such as New York and Maryland, and the quality of its products.

 

"Your name may entice someone to give it a try," he said. "But it's your brand and product quality that are the factors that keep people coming back."

 

Yuvraj Singh, the CEO of Long Island Strain Stars, has stated that customers have returned to purchase more cannabis from Tyson Foods. On the first day of the launch of their Tyson 2.0 flower line, their customers bought a total of $30,000 worth of cannabis products, making the cannabis series one of the top five best-selling products in the store.

 

According to reports, he described its effect as a highly pleasurable and refreshing sensation.

 

Coss Marte, co-owner and CEO of Conbud, has stated that their pharmacy has also attracted more customers to make purchases, selling $10,000 worth of Tyson 2.0 within an hour, which is equivalent to the pharmacy's typical daily sales.

 

Former boxing champion Mike Tyson has emphasized the therapeutic effects of marijuana in his transformation from an arrogant athlete to a disciplined businessman. In an interview, he revealed that less than a decade ago, he was penniless and struggling with a cocaine addiction. Today, he is the owner of one of the most successful celebrity marijuana brands in the country.

 

Tyson stated that his goal is to solidify his legacy as a pioneer of cannabis. "This is more important to me than making money," he declared.

 

Tyson was born into a financially disadvantaged family in Brooklyn and later discovered his boxing talent at a reform school in the north. He quickly became a teenage sensation and eventually won 50 professional matches, most of which were victories by knockout.

 

However, his reputation has been tarnished due to his antics, such as biting Hollyfield's ear, as well as his legal troubles, including a three-year prison sentence for a rape case that he still denies. In 2014, he revealed his dependency on cocaine and claimed that marijuana helped him break free from addiction. He currently resides in Las Vegas and owns a marijuana farm in California.

 

His personal story has attracted many fans, who seem eager to support him. "He has gone through some difficult times, and I can relate to that," said 26-year-old Tony Pedroza, a boxing enthusiast from Brooklyn who was standing in line in Manhattan to see Tyson.

 

Monifa Jones-Tuck and her husband, Troy Tuck, drove from Bethlehem, Pennsylvania to show their support for him. Jones expressed that they have been following Tyson's boxing career since the beginning and admire his progress.

 

"After using marijuana, his mind is currently in a good and calm state," he said. "It suits him well, and he also looks great."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
According to Swiss media outlet Blick, local authorities are strengthening compliance checks on vape products, nicotine pouches and other tobacco-related products following the implementation of Switzerland’s revised Tobacco Products Act. A Basel laboratory tested 32 disposable vapes and e-liquids, with only three meeting regulatory requirements and 21 products banned from sale. Swiss authorities are also expanding retail inspections, laboratory testing and youth purchase checks to enforce the new tobacco and nicotine product rules.
Aug.12
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
Reuters Tracks Big Tobacco’s Shift Beyond Cigarettes as Nicotine Pouches Vie for the Next Growth Curve
As cigarette markets face long-term pressure, major tobacco companies are increasingly turning to nicotine pouches in search of growth beyond combustible tobacco. Reuters has examined whether nicotine pouches can become the next strategic growth platform for companies including Philip Morris International, British American Tobacco and Japan Tobacco. PMI strengthened its position through the acquisition of Swedish Match and its ZYN brand, while BAT and JTI continue expanding their own nicotine pouch portfolios. The category has gained attention because of its smoke-free, device-free format, but regulation, youth-use concerns and market scale will determine whether it can become a long-term growth engine.
Regulations
Aug.18 by 2Firsts Perspectives